

# Steven A Narod

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/381843/steven-a-narod-publications-by-citations.pdf>  
**Version:** 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

438 papers	40,390 citations	83 h-index	195 g-index
467 ext. papers	45,382 ext. citations	7.4 avg, IF	7.04 L-index

#	Paper	IF	Citations
438	A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. <i>Science</i> , <b>1994</b> , 266, 66-71	33.3	4991
437	Triple-negative breast cancer: clinical features and patterns of recurrence. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 4429-34	12.9	2961
436	Identification of the breast cancer susceptibility gene BRCA2. <i>Nature</i> , <b>1995</b> , 378, 789-92	50.4	2780
435	Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. <i>Lancet, The</i> , <b>1994</b> , 343, 692-5	40	1553
434	Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. <i>New England Journal of Medicine</i> , <b>2002</b> , 346, 1616-22	59.2	1363
433	Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 1055-62	2.2	924
432	Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. <i>JAMA - Journal of the American Medical Association</i> , <b>2004</b> , 292, 1317-25	27.4	876
431	Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. <i>Nature Genetics</i> , <b>2002</b> , 31, 55-9	36.3	863
430	Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. <i>American Journal of Human Genetics</i> , <b>2001</b> , 68, 700-10	11	809
429	BRCA1 and BRCA2: 1994 and beyond. <i>Nature Reviews Cancer</i> , <b>2004</b> , 4, 665-76	31.3	694
428	Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. <i>Nature Reviews Cancer</i> , <b>2015</b> , 15, 668-79	31.3	581
427	Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 2328-35	2.2	514
426	Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. <i>Journal of the National Cancer Institute</i> , <b>2006</b> , 98, 1694-706	9.7	486
425	Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. <i>Lancet, The</i> , <b>2000</b> , 356, 1876-81	40	473
424	Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. <i>JAMA - Journal of the American Medical Association</i> , <b>2006</b> , 296, 185-92	27.4	466
423	Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 375-9	2.2	417
422	Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 1547-53	2.2	397

421	Pattern of metastatic spread in triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2009</b> , 115, 423-8	4.4	369
420	Improved survival in women with BRCA-associated ovarian carcinoma. <i>Cancer</i> , <b>2003</b> , 97, 2187-95	6.4	363
419	Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 7491-6	2.2	360
418	Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States. <i>JAMA - Journal of the American Medical Association</i> , <b>2015</b> , 313, 165-73	27.4	356
417	CHEK2 is a multiorgan cancer susceptibility gene. <i>American Journal of Human Genetics</i> , <b>2004</b> , 75, 1131-5	11	349
416	Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 7804-10	2.2	339
415	Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ. <i>JAMA Oncology</i> , <b>2015</b> , 1, 888-96	13.4	330
414	Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. <i>Journal of the National Cancer Institute</i> , <b>1999</b> , 91, 1241-7	9.7	326
413	Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. <i>Gynecologic Oncology</i> , <b>2006</b> , 100, 58-64	4.9	297
412	Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families. <i>Nature Genetics</i> , <b>1994</b> , 8, 392-8	36.3	285
411	Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. <i>Gynecologic Oncology</i> , <b>2011</b> , 121, 353-7	4.9	280
410	International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. <i>International Journal of Cancer</i> , <b>2008</b> , 122, 2017-22	7.5	268
409	Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. <i>Breast Cancer Research and Treatment</i> , <b>2009</b> , 115, 359-63	4.4	266
408	Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. <i>Journal of the National Cancer Institute</i> , <b>2002</b> , 94, 1773-9	9.7	266
407	Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. <i>Nature Medicine</i> , <b>1996</b> , 2, 1179-83	50.5	253
406	BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. <i>American Journal of Human Genetics</i> , <b>2000</b> , 66, 1259-72	11	252
405	Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 2029-34	12.9	234
404	Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. <i>New England Journal of Medicine</i> , <b>2007</b> , 357, 115-23	59.2	230

403	Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing. <i>Preventive Medicine</i> , <b>2000</b> , 31, 75-80	4.3	224
402	Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. <i>International Journal of Cancer</i> , <b>2006</b> , 118, 2281-4	7.5	220
401	Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. <i>PLoS Genetics</i> , <b>2013</b> , 9, e1003212	6	209
400	Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. <i>American Journal of Human Genetics</i> , <b>2000</b> , 66, 1963-8	11	196
399	Can advanced-stage ovarian cancer be cured?. <i>Nature Reviews Clinical Oncology</i> , <b>2016</b> , 13, 255-61	19.4	192
398	Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients. <i>Breast Cancer Research and Treatment</i> , <b>2014</b> , 147, 401-5	4.4	186
397	Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. <i>Lancet Oncology</i> , <b>2007</b> , 8, 26-34	21.7	186
396	Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. <i>BMJ</i> , <b>2014</b> , 348, g226	5.9	181
395	An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Breast Cancer Linkage Consortium. <i>American Journal of Human Genetics</i> , <b>1995</b> , 56, 254-64	11	177
394	A descriptive study of BRCA1 testing and reactions to disclosure of test results. <i>Cancer</i> , <b>1997</b> , 79, 2219-28	28.4	176
393	Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. <i>British Journal of Cancer</i> , <b>2011</b> , 104, 1384-92	8.7	167
392	Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 3747-52	2.2	157
391	Incidence of complications other than urinary incontinence or erectile dysfunction after radical prostatectomy or radiotherapy for prostate cancer: a population-based cohort study. <i>Lancet Oncology</i> , <b>2014</b> , 15, 223-31	21.7	155
390	Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. <i>Journal of the National Cancer Institute</i> , <b>2008</b> , 100, 1361-7	9.7	152
389	Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer. <i>Breast Cancer Research</i> , <b>2012</b> , 14, R110	8.3	151
388	The impact of family history on early detection of prostate cancer. <i>Nature Medicine</i> , <b>1995</b> , 1, 99-101	50.5	150
387	Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 387-91	2.2	141
386	Modifiers of risk of hereditary breast and ovarian cancer. <i>Nature Reviews Cancer</i> , <b>2002</b> , 2, 113-23	31.3	139

385	Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. <i>Journal of the National Cancer Institute</i> , <b>2004</b> , 96, 1094-8	9.7	137
384	NBS1 is a prostate cancer susceptibility gene. <i>Cancer Research</i> , <b>2004</b> , 64, 1215-9	10.1	132
383	Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers. <i>International Journal of Cancer</i> , <b>2005</b> , 117, 988-91	7.5	131
382	Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis. <i>BMJ, The</i> , <b>2016</b> , 352, i851	5.9	126
381	Breast cancer in young women. <i>Nature Reviews Clinical Oncology</i> , <b>2012</b> , 9, 460-70	19.4	125
380	BRCA mutations in the management of breast cancer: the state of the art. <i>Nature Reviews Clinical Oncology</i> , <b>2010</b> , 7, 702-7	19.4	125
379	Germline RECQL mutations are associated with breast cancer susceptibility. <i>Nature Genetics</i> , <b>2015</b> , 47, 643-6	36.3	123
378	Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers. <i>Breast Cancer Research and Treatment</i> , <b>2008</b> , 108, 289-96	4.4	120
377	Congenital anomalies and childhood cancer in Great Britain. <i>American Journal of Human Genetics</i> , <b>1997</b> , 60, 474-85	11	117
376	Gene-body hypermethylation of ATM in peripheral blood DNA of bilateral breast cancer patients. <i>Human Molecular Genetics</i> , <b>2009</b> , 18, 1332-42	5.6	112
375	Rapid progression of prostate cancer in men with a BRCA2 mutation. <i>British Journal of Cancer</i> , <b>2008</b> , 99, 371-4	8.7	112
374	Identification of a novel truncating PALB2 mutation and analysis of its contribution to early-onset breast cancer in French-Canadian women. <i>Breast Cancer Research</i> , <b>2007</b> , 9, R83	8.3	110
373	Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2. <i>Journal of the National Cancer Institute</i> , <b>2013</b> , 105, 141-8	9.7	107
372	Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, 638-44	21.7	106
371	Breast cancer predisposing alleles in Poland. <i>Breast Cancer Research and Treatment</i> , <b>2005</b> , 92, 19-24	4.4	104
370	Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome?. <i>Gynecologic Oncology</i> , <b>2000</b> , 79, 477-81	4.9	104
369	Effect of smoking on breast cancer in carriers of mutant BRCA1 or BRCA2 genes. <i>Journal of the National Cancer Institute</i> , <b>1998</b> , 90, 761-6	9.7	104
368	Survival and cardiovascular events in men treated with testosterone replacement therapy: an intention-to-treat observational cohort study. <i>Lancet Diabetes and Endocrinology, the</i> , <b>2016</b> , 4, 498-506	18.1	101

367	Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. <i>Journal of the National Cancer Institute</i> , <b>2017</b> , 109,	9.7	99
366	Hormone replacement therapy and the risk of breast cancer. <i>Nature Reviews Clinical Oncology</i> , <b>2011</b> , 8, 669-76	19.4	99
365	Incidence of colorectal cancer in BRCA1 and BRCA2 mutation carriers: results from a follow-up study. <i>British Journal of Cancer</i> , <b>2014</b> , 110, 530-4	8.7	95
364	Diet, lifestyle and BRCA-related breast cancer risk among French-Canadians. <i>Breast Cancer Research and Treatment</i> , <b>2006</b> , 98, 285-94	4.4	93
363	Ten-year survival in patients with BRCA1-negative and BRCA1-positive breast cancer. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3191-6	2.2	92
362	Low-grade serous ovarian cancer: A review. <i>Gynecologic Oncology</i> , <b>2016</b> , 143, 433-438	4.9	92
361	A deletion in CHEK2 of 5,395 bp predisposes to breast cancer in Poland. <i>Breast Cancer Research and Treatment</i> , <b>2007</b> , 102, 119-22	4.4	91
360	Frequency of premature menopause in women who carry a BRCA1 or BRCA2 mutation. <i>Fertility and Sterility</i> , <b>2013</b> , 99, 1724-8	4.8	90
359	Modifiers of risk of hereditary breast cancer. <i>Oncogene</i> , <b>2006</b> , 25, 5832-6	9.2	88
358	Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation. <i>British Journal of Cancer</i> , <b>2009</b> , 100, 421-5	8.7	85
357	Psychosocial functioning in women who have undergone bilateral prophylactic mastectomy. <i>Psycho-Oncology</i> , <b>2004</b> , 13, 14-25	3.9	85
356	Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers. <i>JAMA Oncology</i> , <b>2018</b> , 4, 1059-1065	13.4	84
355	The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study. <i>Gynecologic Oncology</i> , <b>2013</b> , 130, 127-31	4.9	83
354	Family history of cancer is a risk factor for squamous cell carcinoma of the head and neck in Brazil: a case-control study. <i>International Journal of Cancer</i> , <b>1995</b> , 63, 769-73	7.5	83
353	Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. <i>JAMA Oncology</i> , <b>2015</b> , 1, 306-13	13.4	81
352	Why have breast cancer mortality rates declined?. <i>Journal of Cancer Policy</i> , <b>2015</b> , 5, 8-17	1	80
351	Changes in body weight and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research</i> , <b>2005</b> , 7, R833-43	8.3	80
350	Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. <i>Lancet Oncology</i> , <b>2006</b> , 7, 402-6	21.7	80

349	Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers. <i>Breast Cancer Research and Treatment</i> , <b>2009</b> , 118, 131-7	4.4	79
348	An evaluation of needs of female BRCA1 and BRCA2 carriers undergoing genetic counselling. <i>Journal of Medical Genetics</i> , <b>2000</b> , 37, 866-74	5.8	78
347	Changes in psychosocial functioning 1 year after mastectomy alone, delayed breast reconstruction, or immediate breast reconstruction. <i>Annals of Surgical Oncology</i> , <b>2012</b> , 19, 233-41	3.1	76
346	CHEK2 mutations and the risk of papillary thyroid cancer. <i>International Journal of Cancer</i> , <b>2015</b> , 137, 548-52	7.5	75
345	Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2015</b> , 150, 71-80	4.4	74
344	Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations. <i>Journal of the National Cancer Institute</i> , <b>2010</b> , 102, 1874-8	9.7	74
343	The impacts of neoadjuvant chemotherapy and of debulking surgery on survival from advanced ovarian cancer. <i>Gynecologic Oncology</i> , <b>2014</b> , 134, 462-7	4.9	73
342	Influence of selected lifestyle factors on breast and ovarian cancer risk in BRCA1 mutation carriers from Poland. <i>Breast Cancer Research and Treatment</i> , <b>2006</b> , 95, 105-9	4.4	71
341	The use of preventive measures among healthy women who carry a BRCA1 or BRCA2 mutation. <i>Familial Cancer</i> , <b>2005</b> , 4, 97-103	3	71
340	Hereditary ovarian cancer in Poland. <i>International Journal of Cancer</i> , <b>2003</b> , 106, 942-5	7.5	70
339	Long-term follow-up of Jewish women with a BRCA1 and BRCA2 mutation who underwent population genetic screening. <i>Breast Cancer Research and Treatment</i> , <b>2012</b> , 133, 735-40	4.4	69
338	Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research</i> , <b>2012</b> , 14, R42	8.3	68
337	Mammographic density and the risk of breast cancer recurrence after breast-conserving surgery. <i>Cancer</i> , <b>2009</b> , 115, 5780-7	6.4	68
336	Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention of breast cancer: a systematic review. <i>Cancer Treatment Reviews</i> , <b>2012</b> , 38, 318-28	14.4	67
335	An inherited NBN mutation is associated with poor prognosis prostate cancer. <i>British Journal of Cancer</i> , <b>2013</b> , 108, 461-8	8.7	67
334	Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , <b>2011</b> , 127, 287-96	4.4	66
333	BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. <i>Journal of the National Cancer Institute</i> , <b>2016</b> , 108,	9.7	65
332	Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status. <i>Gynecologic Oncology</i> , <b>2016</b> , 140, 42-7	4.9	64

331	Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. <i>Cancer Causes and Control</i> , <b>2005</b> , 16, 667-74	2.8	64
330	The impact of prophylactic salpingo-oophorectomy on quality of life and psychological distress in women with a BRCA mutation. <i>Psycho-Oncology</i> , <b>2013</b> , 22, 212-9	3.9	63
329	Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a case-control study. <i>Cancer Causes and Control</i> , <b>2008</b> , 19, 1111-9	2.8	63
328	Why have ovarian cancer mortality rates declined? Part I. Incidence. <i>Gynecologic Oncology</i> , <b>2015</b> , 138, 741-9	4.9	62
327	The relationship between tumour size, nodal status and distant metastases: on the origins of breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2018</b> , 170, 647-656	4.4	61
326	BRCA carriers, prophylactic salpingo-oophorectomy and menopause: clinical management considerations and recommendations. <i>Women's Health</i> , <b>2012</b> , 8, 543-55	3	61
325	BRCA2 hereditary breast cancer pathophenotype. <i>Breast Cancer Research and Treatment</i> , <b>1997</b> , 44, 275-7	4.4	59
324	Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Brazil. <i>Breast Cancer Research and Treatment</i> , <b>2007</b> , 103, 349-53	4.4	59
323	BRCA1 and BRCA2 mutations and the risk for colorectal cancer. <i>Clinical Genetics</i> , <b>2015</b> , 87, 411-8	4	58
322	Breast cancer risk perception among women who have undergone prophylactic bilateral mastectomy. <i>Journal of the National Cancer Institute</i> , <b>2002</b> , 94, 1564-9	9.7	58
321	Association of the Timing of Pregnancy With Survival in Women With Breast Cancer. <i>JAMA Oncology</i> , <b>2017</b> , 3, 659-665	13.4	57
320	Quality of life and health status after prophylactic salpingo-oophorectomy in women who carry a BRCA mutation: A review. <i>Maturitas</i> , <b>2011</b> , 70, 261-5	5	57
319	Current understanding of the epidemiology and clinical implications of BRCA1 and BRCA2 mutations for ovarian cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , <b>2002</b> , 14, 19-26	2.4	57
318	A high prevalence of BRCA1 mutations among breast cancer patients from the Bahamas. <i>Breast Cancer Research and Treatment</i> , <b>2011</b> , 125, 591-6	4.4	55
317	A low frequency of non-founder BRCA1 mutations in Ashkenazi Jewish breast-ovarian cancer families. <i>Human Mutation</i> , <b>2002</b> , 20, 352-7	4.7	55
316	Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers. <i>Breast Cancer Research and Treatment</i> , <b>2014</b> , 143, 579-86	4.4	53
315	Androgens and breast cancer. <i>Steroids</i> , <b>2012</b> , 77, 1-9	2.8	52
314	International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation. <i>British Journal of Cancer</i> , <b>2019</b> , 121, 15-21	8.7	50

313	The prevalence of BRCA1 and BRCA2 mutations among young Mexican women with triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2015</b> , 150, 389-94	4.4	49
312	Diabetes and breast cancer among women with BRCA1 and BRCA2 mutations. <i>Cancer</i> , <b>2011</b> , 117, 1812-86.4	4	49
311	Germline CHEK2 mutations and colorectal cancer risk: different effects of a missense and truncating mutations?. <i>European Journal of Human Genetics</i> , <b>2007</b> , 15, 237-41	5.3	49
310	Polymorphisms in folate metabolizing enzymes and transport proteins and the risk of breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2008</b> , 112, 585-93	4.4	49
309	The impact of a BRCA2 mutation on mortality from screen-detected prostate cancer. <i>British Journal of Cancer</i> , <b>2014</b> , 111, 1238-40	8.7	48
308	Survival of patients with BRCA1-associated breast cancer diagnosed in an MRI-based surveillance program. <i>Breast Cancer Research and Treatment</i> , <b>2013</b> , 139, 155-61	4.4	48
307	Fusion in the ETS gene family and prostate cancer. <i>British Journal of Cancer</i> , <b>2008</b> , 99, 847-51	8.7	47
306	Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation. <i>Gynecologic Oncology</i> , <b>2018</b> , 150, 85-91	4.9	47
305	The spectrum of BRCA1 and BRCA2 mutations in breast cancer patients in the Bahamas. <i>Clinical Genetics</i> , <b>2014</b> , 85, 64-7	4	46
304	Testing for CHEK2 in the cancer genetics clinic: ready for prime time?. <i>Clinical Genetics</i> , <b>2010</b> , 78, 1-7	4	45
303	Founder BRCA1 and BRCA2 mutations in French Canadian ovarian cancer cases unselected for family history. <i>Clinical Genetics</i> , <b>1999</b> , 55, 318-24	4	45
302	Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. <i>International Journal of Cancer</i> , <b>2015</b> , 137, 1136-46	7.5	44
301	Time to disease recurrence in basal-type breast cancers: effects of tumor size and lymph node status. <i>Cancer</i> , <b>2009</b> , 115, 4917-23	6.4	44
300	Hormonal prevention of hereditary breast cancer. <i>Annals of the New York Academy of Sciences</i> , <b>2001</b> , 952, 36-43	6.5	44
299	Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case-control study. <i>Breast Cancer Research and Treatment</i> , <b>2016</b> , 155, 365-73	4.4	43
298	Bilateral breast cancers. <i>Nature Reviews Clinical Oncology</i> , <b>2014</b> , 11, 157-66	19.4	43
297	Patient satisfaction and cancer-related distress among unselected Jewish women undergoing genetic testing for BRCA1 and BRCA2. <i>Clinical Genetics</i> , <b>2010</b> , 78, 411-7	4	42
296	Family history as a predictor of uptake of cancer preventive procedures by women with a BRCA1 or BRCA2 mutation. <i>Clinical Genetics</i> , <b>2008</b> , 73, 474-9	4	42

295	A comparison of bilateral breast cancers in BRCA carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2005</b> , 14, 1534-8	4	42
294	Estrogen receptor status in CHEK2-positive breast cancers: implications for chemoprevention. <i>Clinical Genetics</i> , <b>2009</b> , 75, 72-8	4	41
293	The impact of pregnancy on breast cancer survival in women who carry a BRCA1 or BRCA2 mutation. <i>Breast Cancer Research and Treatment</i> , <b>2013</b> , 142, 177-85	4.4	40
292	BRCA1 and BRCA2 hereditary breast carcinoma phenotypes. <i>Cancer</i> , <b>1997</b> , 80, 543-556	6.4	40
291	Smoking and the risk of breast cancer among carriers of BRCA mutations. <i>International Journal of Cancer</i> , <b>2004</b> , 110, 413-6	7.5	40
290	Impact of microinvasion on breast cancer mortality in women with ductal carcinoma in situ. <i>Breast Cancer Research and Treatment</i> , <b>2018</b> , 167, 787-795	4.4	40
289	Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from Peru. <i>Clinical Genetics</i> , <b>2015</b> , 88, 371-5	4	39
288	Tumour size predicts long-term survival among women with lymph node-positive breast cancer. <i>Current Oncology</i> , <b>2012</b> , 19, 249-53	2.8	39
287	Oophorectomy after menopause and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2012</b> , 21, 1089-96	4	39
286	A low selenium level is associated with lung and laryngeal cancers. <i>PLoS ONE</i> , <b>2013</b> , 8, e59051	3.7	39
285	Why have ovarian cancer mortality rates declined? Part II. Case-fatality. <i>Gynecologic Oncology</i> , <b>2015</b> , 138, 750-6	4.9	38
284	Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , <b>2007</b> , 105, 221-8	4.4	38
283	BRCA1-positive breast cancers in young women from Poland. <i>Breast Cancer Research and Treatment</i> , <b>2006</b> , 99, 71-6	4.4	38
282	The contribution of founder mutations to early-onset breast cancer in French-Canadian women. <i>Clinical Genetics</i> , <b>2009</b> , 76, 421-6	4	37
281	CDKN2A mutation in a non-FAMMM kindred with cancers at multiple sites results in a functionally abnormal protein. <i>International Journal of Cancer</i> , <b>1997</b> , 73, 531-6	7.5	37
280	The incidence of bone metastasis after early-stage breast cancer in Canada. <i>Breast Cancer Research and Treatment</i> , <b>2016</b> , 156, 587-595	4.4	37
279	Genetic risk assessment and prevention: the role of genetic testing panels in breast cancer. <i>Expert Review of Anticancer Therapy</i> , <b>2015</b> , 15, 1315-26	3.5	36
278	Chromosomal instability in cell-free DNA is a serum biomarker for prostate cancer. <i>Clinical Chemistry</i> , <b>2015</b> , 61, 239-48	5.5	35

277	Mutations in Fanconi anemia genes and the risk of esophageal cancer. <i>Human Genetics</i> , <b>2011</b> , 129, 573-83	8.3	35
276	Epidemiologic factors that predict long-term survival following a diagnosis of epithelial ovarian cancer. <i>British Journal of Cancer</i> , <b>2017</b> , 116, 964-971	8.7	34
275	Is invasion a necessary step for metastases in breast cancer?. <i>Breast Cancer Research and Treatment</i> , <b>2018</b> , 169, 9-23	4.4	34
274	The risk of gastric cancer in carriers of CHEK2 mutations. <i>Familial Cancer</i> , <b>2013</b> , 12, 473-8	3	34
273	The role of body size and physical activity on the risk of breast cancer in BRCA mutation carriers. <i>Cancer Causes and Control</i> , <b>2015</b> , 26, 333-44	2.8	34
272	Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. <i>Gynecologic Oncology</i> , <b>2006</b> , 100, 83-8	4.9	34
271	Mutations predisposing to breast cancer in 12 candidate genes in breast cancer patients from Poland. <i>Clinical Genetics</i> , <b>2015</b> , 88, 366-70	4	33
270	The risk of breast cancer in women with a BRCA1 mutation from North America and Poland. <i>International Journal of Cancer</i> , <b>2012</b> , 131, 229-34	7.5	33
269	Fallopian Tube Lesions in Women at High Risk for Ovarian Cancer: A Multicenter Study. <i>Cancer Prevention Research</i> , <b>2018</b> , 11, 697-706	3.2	33
268	Genetic testing for RAD51C mutations: in the clinic and community. <i>Clinical Genetics</i> , <b>2015</b> , 88, 303-12	4	32
267	Multiple primary cancers as a guide to heritability. <i>International Journal of Cancer</i> , <b>2014</b> , 135, 1756-63	7.5	31
266	Early radiation exposures and BRCA1-associated breast cancer in young women from Poland. <i>Breast Cancer Research and Treatment</i> , <b>2008</b> , 112, 581-4	4.4	30
265	CHEK2-positive breast cancers in young Polish women. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 4832-5	12.9	30
264	Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , <b>2014</b> , 146, 421-7	4.4	29
263	The G84E mutation in the HOXB13 gene is associated with an increased risk of prostate cancer in Poland. <i>Prostate</i> , <b>2013</b> , 73, 542-8	4.2	29
262	The prevalence of germ-line TP53 mutations in women diagnosed with breast cancer before age 30. <i>Familial Cancer</i> , <b>2009</b> , 8, 563-7	3	29
261	BRCA1 mutations and prostate cancer in Poland. <i>European Journal of Cancer Prevention</i> , <b>2008</b> , 17, 62-6	2	29
260	The joint effect of smoking and AIB1 on breast cancer risk in BRCA1 mutation carriers. <i>Carcinogenesis</i> , <b>2006</b> , 27, 599-605	4.6	29

259	Treatment of infertility does not increase the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. <i>Fertility and Sterility</i> , <b>2016</b> , 105, 781-785	4.8	28
258	Methylation of the BRCA1 promoter in peripheral blood DNA is associated with triple-negative and medullary breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2014</b> , 148, 615-22	4.4	28
257	Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Cuba. <i>Familial Cancer</i> , <b>2008</b> , 7, 275-9	3	28
256	The expected benefit of preventive mastectomy on breast cancer incidence and mortality in BRCA mutation carriers, by age at mastectomy. <i>Breast Cancer Research and Treatment</i> , <b>2018</b> , 167, 263-267	4.4	27
255	Oestrogen receptor status, treatment and breast cancer prognosis in Icelandic BRCA2 mutation carriers. <i>British Journal of Cancer</i> , <b>2016</b> , 115, 776-83	8.7	27
254	Mutations of the MYH gene do not substantially contribute to the risk of breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2009</b> , 114, 575-8	4.4	27
253	Performance analysis of a machine learning flagging system used to identify a group of individuals at a high risk for colorectal cancer. <i>PLoS ONE</i> , <b>2017</b> , 12, e0171759	3.7	26
252	The relationship between local recurrence and death in early-stage breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2016</b> , 155, 175-85	4.4	26
251	Recurrent mutations of BRCA1 and BRCA2 in Poland: an update. <i>Clinical Genetics</i> , <b>2015</b> , 87, 288-92	4	26
250	Identification and Validation of a Five MicroRNA Signature Predictive of Prostate Cancer Recurrence and Metastasis: A Cohort Study. <i>Journal of Cancer</i> , <b>2015</b> , 6, 1160-71	4.5	26
249	PPM1D mutations in circulating white blood cells and the risk for ovarian cancer. <i>Journal of the National Cancer Institute</i> , <b>2014</b> , 106, djt323	9.7	26
248	Thyroid hormone receptor $\beta$ in breast cancer: prognostic and therapeutic implications. <i>Breast Cancer Research and Treatment</i> , <b>2015</b> , 149, 293-301	4.4	25
247	A prospective study of mastectomy patients with and without delayed breast reconstruction: long-term psychosocial functioning in the breast cancer survivorship period. <i>Journal of Surgical Oncology</i> , <b>2015</b> , 111, 258-64	2.8	25
246	Modes of delivery of genetic testing services and the uptake of cancer risk management strategies in BRCA1 and BRCA2 carriers. <i>Clinical Genetics</i> , <b>2014</b> , 85, 49-53	4	25
245	Revisiting breast cancer patients who previously tested negative for BRCA mutations using a 12-gene panel. <i>Breast Cancer Research and Treatment</i> , <b>2017</b> , 161, 135-142	4.4	25
244	Factors associated with breast cancer mortality after local recurrence. <i>Current Oncology</i> , <b>2014</b> , 21, e418-25	2.5	25
243	Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy?. <i>Breast Cancer Research and Treatment</i> , <b>2013</b> , 138, 273-9	4.4	25
242	Age of diagnosis, tumor size, and survival after breast cancer: implications for mammographic screening. <i>Breast Cancer Research and Treatment</i> , <b>2011</b> , 128, 259-66	4.4	25

241	The contribution of founder mutations in BRCA1 to breast and ovarian cancer in Lithuania. <i>Clinical Genetics</i> , <b>2010</b> , 78, 373-6	4	25
240	BRCA1 and BRCA2 families and the risk of skin cancer. <i>Familial Cancer</i> , <b>2010</b> , 9, 489-93	3	25
239	Plasma osteoprotegerin and breast cancer risk in BRCA1 and BRCA2 mutation carriers. <i>Oncotarget</i> , <b>2016</b> , 7, 86687-86694	3.3	25
238	Personalised medicine and population health: breast and ovarian cancer. <i>Human Genetics</i> , <b>2018</b> , 137, 769-778	6.3	25
237	The spectrum of mutations predisposing to familial breast cancer in Poland. <i>International Journal of Cancer</i> , <b>2019</b> , 145, 3311-3320	7.5	24
236	Why have ovarian cancer mortality rates declined? Part III. Prospects for the future. <i>Gynecologic Oncology</i> , <b>2015</b> , 138, 757-61	4.9	24
235	Recurrent BRCA1 and BRCA2 mutations in Mexican women with breast cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2015</b> , 24, 498-505	4	24
234	A comparison of the detection of BRCA mutation carriers through the provision of Jewish population-based genetic testing compared with clinic-based genetic testing. <i>British Journal of Cancer</i> , <b>2013</b> , 109, 777-9	8.7	24
233	Risk factors for non-invasive lesions of the fallopian tube in BRCA mutation carriers. <i>Gynecologic Oncology</i> , <b>2010</b> , 118, 295-8	4.9	24
232	Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted?. <i>Gynecologic Oncology</i> , <b>2017</b> , 145, 346-351	4.9	23
231	Risk factors for endometrial cancer among women with a BRCA1 or BRCA2 mutation: a case control study. <i>Familial Cancer</i> , <b>2015</b> , 14, 383-91	3	23
230	Serum selenium levels predict survival after breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2018</b> , 167, 591-598	4.4	23
229	Preferences for breast cancer risk reduction among BRCA1/BRCA2 mutation carriers: a discrete-choice experiment. <i>Breast Cancer Research and Treatment</i> , <b>2017</b> , 165, 433-444	4.4	23
228	The R337H mutation in TP53 and breast cancer in Brazil. <i>Hereditary Cancer in Clinical Practice</i> , <b>2012</b> , 10, 3	2.3	23
227	International rates of breast reconstruction after prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers. <i>Annals of Surgical Oncology</i> , <b>2013</b> , 20, 3817-22	3.1	23
226	The impact of contralateral mastectomy on mortality in BRCA1 and BRCA2 mutation carriers with breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2011</b> , 128, 581-3	4.4	23
225	Smoking and the risk of breast cancer in BRCA1 and BRCA2 carriers: an update. <i>Breast Cancer Research and Treatment</i> , <b>2009</b> , 114, 127-35	4.4	23
224	Direct-to-patient BRCA1 testing: the Twoj Styl experience. <i>Breast Cancer Research and Treatment</i> , <b>2006</b> , 100, 239-45	4.4	23

223	Effects of bilateral salpingo-oophorectomy on menopausal symptoms and sexual functioning among women with a BRCA1 or BRCA2 mutation. <i>Gynecologic Oncology</i> , <b>2019</b> , 152, 145-150	4.9	23
222	Complications following surgery with or without radiotherapy or radiotherapy alone for prostate cancer. <i>British Journal of Cancer</i> , <b>2015</b> , 112, 977-82	8.7	22
221	The prognostic effect of estrogen receptor status differs for younger versus older breast cancer patients. <i>Breast Cancer Research and Treatment</i> , <b>2017</b> , 165, 391-402	4.4	21
220	Association Between Use of Antithrombotic Medication and Hematuria-Related Complications. <i>JAMA - Journal of the American Medical Association</i> , <b>2017</b> , 318, 1260-1271	27.4	21
219	Can we prevent BRCA1-associated breast cancer by RANKL inhibition?. <i>Breast Cancer Research and Treatment</i> , <b>2017</b> , 161, 11-16	4.4	21
218	Complications after radical prostatectomy or radiotherapy for prostate cancer: results of a population-based, propensity score-matched analysis. <i>Urology</i> , <b>2015</b> , 85, 621-7	1.6	21
217	BRCA1 and BRCA2 mutations among familial breast cancer patients from Costa Rica. <i>Clinical Genetics</i> , <b>2012</b> , 82, 484-8	4	21
216	The contribution of founder mutations in BRCA1 to breast cancer in Belarus. <i>Clinical Genetics</i> , <b>2010</b> , 78, 377-80	4	21
215	Risk factors for carcinoma of the fallopian tube in women with and without a germline BRCA mutation. <i>Gynecologic Oncology</i> , <b>2010</b> , 118, 155-9	4.9	21
214	Telomere length and mortality following a diagnosis of ovarian cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2014</b> , 23, 2603-6	4	20
213	A common nonsense mutation of the BLM gene and prostate cancer risk and survival. <i>Gene</i> , <b>2013</b> , 532, 173-6	3.8	20
212	BRCA1 mutations and colorectal cancer in Poland. <i>Familial Cancer</i> , <b>2010</b> , 9, 541-4	3	20
211	Epistatic relationship between the cancer susceptibility genes CHEK2 and p27. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2007</b> , 16, 572-6	4	20
210	Germline RECQL mutations in high risk Chinese breast cancer patients. <i>Breast Cancer Research and Treatment</i> , <b>2016</b> , 157, 211-215	4.4	20
209	Physical activity during adolescence and young adulthood and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , <b>2018</b> , 169, 561-571	4.4	19
208	Mammography screening and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a prospective study. <i>Breast Cancer Research and Treatment</i> , <b>2014</b> , 147, 113-8	4.4	19
207	Plasma micronutrients, trace elements, and breast cancer in BRCA1 mutation carriers: an exploratory study. <i>Cancer Causes and Control</i> , <b>2012</b> , 23, 1065-74	2.8	19
206	Prevalence of founder mutations in the BRCA1 and BRCA2 genes among unaffected women from the Bahamas. <i>Clinical Genetics</i> , <b>2016</b> , 89, 328-31	4	18

205	is A Low/Moderate Breast Cancer Risk Gene: Evidence Based on An Association Study of the Central European p.Q564X Recurrent Mutation. <i>Cancers</i> , <b>2019</b> , 11,	6.6	18
204	Functionally Null Missense Mutation Associates Strongly with Ovarian Carcinoma. <i>Cancer Research</i> , <b>2017</b> , 77, 4517-4529	10.1	18
203	Disappearing breast cancers. <i>Current Oncology</i> , <b>2012</b> , 19, 59-60	2.8	18
202	Genetics of breast and ovarian cancer. <i>British Medical Bulletin</i> , <b>1994</b> , 50, 656-76	5.4	18
201	Serum selenium levels and the risk of progression of laryngeal cancer. <i>PLoS ONE</i> , <b>2018</b> , 13, e0184873	3.7	17
200	BRCA1 mRNA levels following a 4-6-week intervention with oral 3,3Pdiindolylmethane. <i>British Journal of Cancer</i> , <b>2014</b> , 111, 1269-74	8.7	17
199	Cardiovascular and Skeletal-related Events Following Localized Prostate Cancer Treatment: Role of Surgery, Radiotherapy, and Androgen Deprivation. <i>Urology</i> , <b>2016</b> , 97, 145-152	1.6	17
198	Plasma folate, vitamin B-6, and vitamin B-12 and breast cancer risk in BRCA1- and BRCA2-mutation carriers: a prospective study. <i>American Journal of Clinical Nutrition</i> , <b>2016</b> , 104, 671-7	7	17
197	Germline RAP80 mutations and susceptibility to breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2009</b> , 113, 377-81	4.4	16
196	CYP1B1 and predisposition to breast cancer in Poland. <i>Breast Cancer Research and Treatment</i> , <b>2007</b> , 106, 383-8	4.4	16
195	Variation in rates of uptake of preventive options by Canadian women carrying the BRCA1 or BRCA2 genetic mutation. <i>Open Medicine</i> , <b>2007</b> , 1, e92-8		16
194	Germline TP53 mutational spectrum in French Canadians with breast cancer. <i>BMC Medical Genetics</i> , <b>2015</b> , 16, 24	2.1	15
193	Rates of risk-reducing surgery in Israeli BRCA1 and BRCA2 mutation carriers. <i>Clinical Genetics</i> , <b>2014</b> , 85, 68-71	4	15
192	Tumour diploidy and survival in breast cancer patients with BRCA2 mutations. <i>Breast Cancer Research and Treatment</i> , <b>2013</b> , 140, 375-84	4.4	15
191	Strategies for recruitment of relatives of BRCA mutation carriers to a genetic testing program in the Bahamas. <i>Clinical Genetics</i> , <b>2015</b> , 88, 182-6	4	15
190	Preventing ovarian cancer through genetic testing: a population-based study. <i>Clinical Genetics</i> , <b>2014</b> , 86, 496-9	4	15
189	Excess of congenital abnormalities in French-Canadian children with neuroblastoma: a case series study from Montréal. <i>Medical and Pediatric Oncology</i> , <b>1997</b> , 29, 272-9		15
188	Clinical practice guidelines for BRCA1 and BRCA2 genetic testing. <i>European Journal of Cancer</i> , <b>2021</b> , 146, 30-47	7.5	15

187	Genetic testing for BRCA1 and BRCA2 in the Province of Ontario. <i>Clinical Genetics</i> , <b>2016</b> , 89, 304-11	4	14
186	The association between smoking and cancer incidence in BRCA1 and BRCA2 mutation carriers. <i>International Journal of Cancer</i> , <b>2018</b> , 142, 2263-2272	7.5	14
185	Age-specific incidence rates for breast cancer in carriers of BRCA1 mutations from Norway. <i>Clinical Genetics</i> , <b>2013</b> , 83, 88-91	4	14
184	Multiple therapeutic and preventive effects of 3,3Pdiindolylmethane on cancers including prostate cancer and high grade prostatic intraepithelial neoplasia. <i>Journal of Biomedical Research</i> , <b>2014</b> , 28, 339-48	1.5	14
183	Correlation between germline mutations in MMR genes and microsatellite instability in ovarian cancer specimens. <i>Familial Cancer</i> , <b>2017</b> , 16, 351-355	3	13
182	Oestrogen receptor status and survival in women with BRCA2-associated breast cancer. <i>British Journal of Cancer</i> , <b>2019</b> , 120, 398-403	8.7	13
181	Parental origin of mutation and the risk of breast cancer in a prospective study of women with a BRCA1 or BRCA2 mutation. <i>Clinical Genetics</i> , <b>2013</b> , 84, 43-6	4	13
180	Frequency of germline PALB2 mutations among women with epithelial ovarian cancer. <i>Familial Cancer</i> , <b>2017</b> , 16, 29-34	3	13
179	Health care provider recommendations for reducing cancer risks among women with a BRCA1 or BRCA2 mutation. <i>Clinical Genetics</i> , <b>2014</b> , 85, 21-30	4	13
178	BRCA1 haploinsufficiency: consequences for breast cancer. <i>Women's Health</i> , <b>2012</b> , 8, 127-9	3	13
177	Androgen receptor and familial prostate cancer. <i>Nature Medicine</i> , <b>1995</b> , 1, 848-9	50.5	13
176	Genetic heterogeneity of early-onset familial breast cancer. <i>Human Genetics</i> , <b>1992</b> , 89, 381-3	6.3	13
175	Predictors of survival for breast cancer patients with a BRCA1 mutation. <i>Breast Cancer Research and Treatment</i> , <b>2018</b> , 168, 513-521	4.4	12
174	Estimating survival rates after ovarian cancer among women tested for BRCA1 and BRCA2 mutations. <i>Clinical Genetics</i> , <b>2013</b> , 83, 232-7	4	12
173	The impact of nodal micrometastasis on mortality among women with early-stage breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2017</b> , 161, 103-115	4.4	12
172	Does family history predict the age at onset of new breast cancers in BRCA1 and BRCA2 mutation-positive families?. <i>Clinical Genetics</i> , <b>2010</b> , 77, 273-9	4	12
171	Tamoxifen and the risk of ovarian cancer in BRCA1 mutation carriers. <i>Gynecologic Oncology</i> , <b>2009</b> , 115, 135-137	4.9	12
170	Screening for BRCA1 and BRCA2 mutations in breast cancer patients from Mexico: the public health perspective. <i>Salud Publica De Mexico</i> , <b>2009</b> , 51 Suppl 2, s191-6	1.7	12

169	The therapeutic ratio is preserved for radiotherapy or cisplatin treatment in BRCA2-mutated prostate cancers. <i>Canadian Urological Association Journal</i> , <b>2011</b> , 5, E31-5	1.2	12
168	BRCA1 promoter methylation in peripheral blood is associated with the risk of triple-negative breast cancer. <i>International Journal of Cancer</i> , <b>2020</b> , 146, 1293-1298	7.5	12
167	A Matched Case-Control Study of Risk Factors for Breast Cancer Risk in Vietnam. <i>International Journal of Breast Cancer</i> , <b>2016</b> , 2016, 7164623	2.3	12
166	Predictors of time to death after distant recurrence in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , <b>2019</b> , 173, 465-474	4.4	12
165	Time to death in breast cancer patients as an indicator of treatment response. <i>Breast Cancer Research and Treatment</i> , <b>2018</b> , 172, 659-669	4.4	12
164	Predictors of long-term cancer-related distress among female BRCA1 and BRCA2 mutation carriers without a cancer diagnosis: an international analysis. <i>British Journal of Cancer</i> , <b>2020</b> , 123, 268-274	8.7	11
163	New Rates of Interventions to Manage Complications of Modern Prostate Cancer Treatment in Older Men. <i>European Urology</i> , <b>2016</b> , 69, 933-41	10.2	11
162	Genetics of endometrial cancer. <i>Familial Cancer</i> , <b>2014</b> , 13, 499-505	3	11
161	Screening for BRCA1 and BRCA2 mutations among French-Canadian breast cancer cases attending an outpatient clinic in Montreal. <i>Clinical Genetics</i> , <b>2014</b> , 85, 31-5	4	11
160	Screening with magnetic resonance imaging, mammography and ultrasound in women at average and intermediate risk of breast cancer. <i>Hereditary Cancer in Clinical Practice</i> , <b>2017</b> , 15, 4	2.3	11
159	Tumour characteristics among women with very low-risk breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2012</b> , 134, 1241-6	4.4	11
158	Screening of women at high risk for breast cancer. <i>Preventive Medicine</i> , <b>2011</b> , 53, 127-30	4.3	11
157	Compliance with tamoxifen in women with breast cancer and a BRCA1 or BRCA2 mutation. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, e698-9; author reply e700	2.2	11
156	A protein truncating BRCA1 allele with a low penetrance of breast cancer. <i>Journal of Medical Genetics</i> , <b>2004</b> , 41, e130	5.8	11
155	The impact of oophorectomy on survival after breast cancer in BRCA1-positive breast cancer patients. <i>Breast Cancer Research and Treatment</i> , <b>2016</b> , 156, 371-8	4.4	11
154	Folic acid supplement use and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a case-control study. <i>Breast Cancer Research and Treatment</i> , <b>2019</b> , 174, 741-748	4.4	10
153	Blood cadmium levels as a marker for early lung cancer detection. <i>Journal of Trace Elements in Medicine and Biology</i> , <b>2021</b> , 64, 126682	4.1	10
152	CCR 20th Anniversary Commentary: Triple-Negative Breast Cancer in 2015Still in the Ballpark. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 3813-4	12.9	9

151	Changes in Bone Mineral Density After Prophylactic Bilateral Salpingo-Oophorectomy in Carriers of a BRCA Mutation. <i>JAMA Network Open</i> , <b>2019</b> , 2, e198420	10.4	9
150	Survival from breast cancer in patients with CHEK2 mutations. <i>Breast Cancer Research and Treatment</i> , <b>2014</b> , 144, 397-403	4.4	9
149	Early-onset breast cancer: what do we know about the risk factors?: A Countercurrents Series. <i>Current Oncology</i> , <b>2011</b> , 18, 204-5	2.8	9
148	A survey of preventive measures among BRCA1 mutation carriers from Poland. <i>Clinical Genetics</i> , <b>2007</b> , 71, 153-7	4	9
147	The risk of breast cancer in BRCA1 and BRCA2 mutation carriers without a first-degree relative with breast cancer. <i>Clinical Genetics</i> , <b>2018</b> , 93, 1063-1068	4	9
146	Blood arsenic levels and the risk of familial breast cancer in Poland. <i>International Journal of Cancer</i> , <b>2020</b> , 146, 2721-2727	7.5	9
145	Prediction of findings at screening colonoscopy using a machine learning algorithm based on complete blood counts (ColonFlag). <i>PLoS ONE</i> , <b>2018</b> , 13, e0207848	3.7	9
144	A model for estimating ovarian cancer risk: application for preventive oophorectomy. <i>Gynecologic Oncology</i> , <b>2015</b> , 139, 242-7	4.9	8
143	Uninterrupted Sedentary Behavior Downregulates BRCA1 Gene Expression. <i>Cancer Prevention Research</i> , <b>2016</b> , 9, 83-8	3.2	8
142	Prospective evaluation of alcohol consumption and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , <b>2015</b> , 151, 435-41	4.4	8
141	A prior diagnosis of breast cancer is a risk factor for breast cancer in BRCA1 and BRCA2 carriers. <i>Current Oncology</i> , <b>2014</b> , 21, 64-8	2.8	8
140	Anthropometric measures and risk of ovarian cancer among BRCA1 and BRCA2 mutation carriers. <i>Obesity</i> , <b>2012</b> , 20, 1288-92	8	8
139	Genes, the environment, and breast cancer. <i>Lancet, The</i> , <b>2010</b> , 375, 2123-4	4.0	8
138	A model for breast cancer risk based on stem-cell theory. <i>Current Oncology</i> , <b>2012</b> , 19, 9-11	2.8	8
137	Mutations in ATM, NBN and BRCA2 predispose to aggressive prostate cancer in Poland. <i>International Journal of Cancer</i> , <b>2020</b> , 147, 2793-2800	7.5	8
136	A model for ovarian cancer progression based on inherent resistance. <i>Gynecologic Oncology</i> , <b>2016</b> , 142, 484-9	4.9	8
135	Age at first full-term birth and breast cancer risk in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , <b>2018</b> , 171, 421-426	4.4	8
134	Predicting the presence of colon cancer in members of a health maintenance organisation by evaluating analytes from standard laboratory records. <i>British Journal of Cancer</i> , <b>2017</b> , 116, 944-950	8.7	7

133	A Population-Based Cross-Sectional Study Comparing Breast Cancer Stage at Diagnosis between Immigrant and Canadian-Born Women in Ontario. <i>Breast Journal</i> , <b>2017</b> , 23, 525-536	1.2	7
132	Thyroid hormone receptor beta-1 expression in early breast cancer: a validation study. <i>Breast Cancer Research and Treatment</i> , <b>2018</b> , 171, 709-717	4.4	7
131	Exome Sequencing in and -Negative Greek Families Identifies and as Candidate Risk Genes for Hereditary Breast Cancer. <i>Frontiers in Genetics</i> , <b>2019</b> , 10, 1005	4.5	7
130	Risk Factors for Premenopausal Breast Cancer in Bangladesh. <i>International Journal of Breast Cancer</i> , <b>2015</b> , 2015, 612042	2.3	7
129	Genetic variants associated with breast-cancer risk. <i>Lancet Oncology, The</i> , <b>2011</b> , 12, 415-6	21.7	7
128	Prevalence of Recurrent Mutations Predisposing to Breast Cancer in Early-Onset Breast Cancer Patients from Poland. <i>Cancers</i> , <b>2020</b> , 12,	6.6	7
127	The risk of contralateral breast cancer in daughters of women with and without breast cancer. <i>Clinical Genetics</i> , <b>2016</b> , 89, 332-5	4	7
126	Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , <b>2019</b> , 175, 443-449	4.4	7
125	Bilateral Mastectomy in Women With Unilateral Breast Cancer: A Review. <i>JAMA Surgery</i> , <b>2021</b> , 156, 569-576	5.6	7
124	Computer-Assisted Flagging of Individuals at High Risk of Colorectal Cancer in a Large Health Maintenance Organization Using the ColonFlag Test. <i>JCO Clinical Cancer Informatics</i> , <b>2018</b> , 2, 1-8	5.2	7
123	Denosumab and breast cancer risk in postmenopausal women: a population-based cohort study. <i>British Journal of Cancer</i> , <b>2018</b> , 119, 1421-1427	8.7	7
122	A high frequency of PALB2 mutations in Jamaican patients with breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2017</b> , 162, 591-596	4.4	6
121	Inherited variants in XRCC2 and the risk of breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2019</b> , 178, 657-663	4.4	6
120	A comparison of ovarian cancer mortality in women with BRCA1 mutations undergoing annual ultrasound screening or preventive oophorectomy. <i>Gynecologic Oncology</i> , <b>2019</b> , 155, 270-274	4.9	6
119	Prospective evaluation of body size and breast cancer risk among BRCA1 and BRCA2 mutation carriers. <i>International Journal of Epidemiology</i> , <b>2018</b> , 47, 987-997	7.8	6
118	Clinical implications of genetic testing for BRCA1 and BRCA2 mutations in Austria. <i>Clinical Genetics</i> , <b>2014</b> , 85, 72-5	4	6
117	Earlier age of onset in BRCA carriers-anticipation or cohort effect?: A Countercurrents Series. <i>Current Oncology</i> , <b>2011</b> , 18, 257-8	2.8	6
116	Ovarian cancer and HRT in the Million Women Study. <i>Lancet, The</i> , <b>2007</b> , 369, 1667-8	40	6

115	Reduced BRCA1 transcript levels in freshly isolated blood leukocytes from BRCA1 mutation carriers is mutation specific. <i>Breast Cancer Research</i> , <b>2016</b> , 18, 87	8.3	6
114	CHEK2 Alleles Predispose to Renal Cancer in Poland. <i>JAMA Oncology</i> , <b>2019</b> , 5, 576	13.4	6
113	A clinically structured and partnered approach to genetic testing in Trinidadian women with breast cancer and their families. <i>Breast Cancer Research and Treatment</i> , <b>2019</b> , 174, 469-477	4.4	6
112	Which women decide to take tamoxifen?. <i>Breast Cancer Research and Treatment</i> , <b>2017</b> , 164, 149-155	4.4	5
111	Serum osteoprotegerin levels and mammographic density among high-risk women. <i>Cancer Causes and Control</i> , <b>2018</b> , 29, 507-517	2.8	5
110	Allelic modification of breast cancer risk in women with an NBN mutation. <i>Breast Cancer Research and Treatment</i> , <b>2019</b> , 178, 427-431	4.4	5
109	A generalizable relationship between mortality and time-to-death among breast cancer patients can be explained by tumour dormancy. <i>Breast Cancer Research and Treatment</i> , <b>2019</b> , 177, 691-703	4.4	5
108	Should hysterectomy complement prophylactic salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers?. <i>Gynecologic Oncology</i> , <b>2014</b> , 134, 219-21	4.9	5
107	Counterpoint re: "Mammography screening-sticking to the science". <i>Current Oncology</i> , <b>2015</b> , 22, 177	2.8	5
106	The effect of oral 3,3Pdiindolylmethane supplementation on the 2:16EOHE ratio in BRCA1 mutation carriers. <i>Familial Cancer</i> , <b>2015</b> , 14, 281-6	3	5
105	Hereditary breast carcinoma syndromes. <i>Cancer</i> , <b>1997</b> , 80, 537-542	6.4	5
104	What options for treatment of hereditary breast cancer?. <i>Lancet, The</i> , <b>2002</b> , 359, 1451-2	4.0	5
103	Plasma RANKL levels are not associated with breast cancer risk in and mutation carriers. <i>Oncotarget</i> , <b>2019</b> , 10, 2475-2483	3.3	5
102	Factors associated with use of hormone therapy after preventive oophorectomy in BRCA mutation carriers. <i>Menopause</i> , <b>2020</b> , 27, 1396-1402	2.5	5
101	Retesting of women who are negative for a and mutation using a 20-gene panel. <i>Journal of Medical Genetics</i> , <b>2020</b> , 57, 380-384	5.8	5
100	Gene Sequencing for Pathogenic Variants Among Adults With Breast and Ovarian Cancer in the Caribbean. <i>JAMA Network Open</i> , <b>2021</b> , 4, e210307	10.4	5
99	Recurrent Mutations in , , and in Polish Patients with Ovarian Cancer. <i>Cancers</i> , <b>2021</b> , 13,	6.6	5
98	Use of bone-modifying agents among breast cancer patients with bone metastasis: evidence from oncology practices in the US. <i>Clinical Epidemiology</i> , <b>2018</b> , 10, 1349-1358	5.9	5

97	The effect of selection and referral biases for the treatment of localised prostate cancer with surgery or radiation. <i>British Journal of Cancer</i> , <b>2018</b> , 118, 1399-1405	8.7	5
96	Does the age of breast cancer diagnosis in first-degree relatives impact on the risk of breast cancer in BRCA1 and BRCA2 mutation carriers?. <i>Breast Cancer Research and Treatment</i> , <b>2015</b> , 154, 163-9	4.4	4
95	Prophylactic salpingectomy for the prevention of ovarian cancer: Who should we target?. <i>International Journal of Cancer</i> , <b>2020</b> , 147, 1245-1251	7.5	4
94	Short report: Follow-up of Bahamian women with a BRCA1 or BRCA2 mutation. <i>Molecular Genetics &amp; Genomic Medicine</i> , <b>2018</b> , 6, 301-304	2.3	4
93	Human kallikrein-2 gene and protein expression predicts prostate cancer at repeat biopsy. <i>SpringerPlus</i> , <b>2014</b> , 3, 295		4
92	BRCA1 founder mutations compared to ovarian cancer in Belarus. <i>Familial Cancer</i> , <b>2014</b> , 13, 445-7	3	4
91	Serum Selenium Level Predicts 10-Year Survival after Breast Cancer. <i>Nutrients</i> , <b>2021</b> , 13,	6.7	4
90	The risk of contralateral breast cancer: a SEER-based analysis. <i>British Journal of Cancer</i> , <b>2021</b> , 125, 601-610	8.7	4
89	Impact of a prior diagnosis of DCIS on survival from invasive breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2016</b> , 158, 385-93	4.4	4
88	Age-specific risks of incident, contralateral and ipsilateral breast cancer among 1776 Polish BRCA1 mutation carriers. <i>Breast Cancer Research and Treatment</i> , <b>2019</b> , 174, 769-774	4.4	4
87	Premenopausal Plasma Osteoprotegerin and Breast Cancer Risk: A Case-Control Analysis Nested within the Nurses' Health Study II. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2020</b> , 29, 1264-1270	4	4
86	Rapid Genetic Testing for BRCA1 and BRCA2 Mutations at the Time of Breast Cancer Diagnosis: An Observational Study. <i>Annals of Surgical Oncology</i> , <b>2021</b> , 28, 2219-2226	3.1	4
85	Population-Based Genetic Testing for BRCA1 and BRCA2. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 517	2.2	4
84	Incidence of Cancer Among Adults With Thrombocytosis in Ontario, Canada. <i>JAMA Network Open</i> , <b>2021</b> , 4, e2120633	10.4	4
83	Survival Differences in Women with and without Autologous Breast Reconstruction after Mastectomy for Breast Cancer. <i>Plastic and Reconstructive Surgery - Global Open</i> , <b>2017</b> , 5, e1281	1.2	3
82	Estimating the effect of immortal-time bias in urological research: a case example of testosterone-replacement therapy. <i>BJU International</i> , <b>2017</b> , 120, 584-590	5.6	3
81	Response. <i>Journal of the National Cancer Institute</i> , <b>2017</b> , 109,	9.7	3
80	Re: Pan-Canadian study of mammography screening and mortality from breast cancer. <i>Journal of the National Cancer Institute</i> , <b>2015</b> , 107,	9.7	3

79	A comparison of two models for breast cancer mortality for women with ductal carcinoma in situ: an SEER-based analysis. <i>Breast Cancer Research and Treatment</i> , <b>2018</b> , 169, 587-594	4.4	3
78	Frequency of and causative founder variants in ovarian cancer patients in South-East Poland. <i>Hereditary Cancer in Clinical Practice</i> , <b>2018</b> , 16, 6	2.3	3
77	rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. <i>International Journal of Molecular Sciences</i> , <b>2018</b> , 19,	6.3	3
76	Predictors of mammographic density among women with a strong family history of breast cancer. <i>BMC Cancer</i> , <b>2019</b> , 19, 631	4.8	3
75	Interest of individuals from BRCA families to participate in research studies focused on male BRCA carriers. <i>Familial Cancer</i> , <b>2013</b> , 12, 615-9	3	3
74	Breast Cancer Genetics for Plastic Surgeons. <i>Plastic and Reconstructive Surgery</i> , <b>2017</b> , 140, 455-460	2.7	3
73	The impact of an expanded genetic testing program and selective oophorectomy on the incidence of ovarian cancer in West Pomerania. <i>Clinical Genetics</i> , <b>2017</b> , 91, 322-327	4	3
72	Breast cancer and the environment: what is left to learn?: A Countercurrents Series. <i>Current Oncology</i> , <b>2013</b> , 20, 8-9	2.8	3
71	The tip of the iceberg: a countercurrents series. <i>Current Oncology</i> , <b>2012</b> , 19, 129-30	2.8	3
70	Analysis of BRCA1 mutations in a Pakistani family with hereditary breast and ovarian cancer syndrome <b>1998</b> , 78, 386-387		3
69	Platelet Count and Survival after Cancer.. <i>Cancers</i> , <b>2022</b> , 14,	6.6	3
68	Analysis of Platelet Count and New Cancer Diagnosis Over a 10-Year Period.. <i>JAMA Network Open</i> , <b>2022</b> , 5, e2141633	10.4	3
67	Does preventive oophorectomy increase the risk of depression in BRCA mutation carriers?. <i>Menopause</i> , <b>2020</b> , 27, 156-161	2.5	3
66	Survival Differences in Chinese Versus White Women With Breast Cancer in the United States: A SEER-Based Analysis. <i>JCO Global Oncology</i> , <b>2020</b> , 6, 1582-1592	3.7	3
65	Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation. <i>Gynecologic Oncology</i> , <b>2020</b> , 159, 820-826	4.9	3
64	Hospitalizations to Manage Complications of Modern Prostate Cancer Treatment in Older Men. <i>Urology</i> , <b>2016</b> , 96, 142-147	1.6	3
63	Patient reported experiences following laparoscopic prophylactic bilateral salpingo-oophorectomy or salpingectomy in an ambulatory care hospital. <i>Familial Cancer</i> , <b>2021</b> , 20, 103-110	3	3
62	Testing Ashkenazi Jewish Women for Mutations Predisposing to Breast Cancer in Genes Other Than BRCA1 and BRCA2. <i>JAMA Oncology</i> , <b>2018</b> , 4, 1012	13.4	3

61	MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc). <i>Lancet Oncology, The</i> , <b>2019</b> , 20, e465	21.7	2
60	Is There a Future for Ovarian Cancer Screening?. <i>JAMA Internal Medicine</i> , <b>2018</b> , 178, 611-612	11.5	2
59	Clinical characteristics of breast cancer in patients with an NBS1 mutation. <i>Breast Cancer Research and Treatment</i> , <b>2013</b> , 141, 471-6	4.4	2
58	Ten types of breast cancer?. <i>Lancet, The</i> , <b>2012</b> , 380, 1212-3	4.0	2
57	Family with Graves disease, multinodular goiter, nonmedullary thyroid carcinoma, and alveolar rhabdomyosarcoma <b>1997</b> , 72, 30-33		2
56	Power of the admixture test to detect genetic heterogeneity. <i>Genetic Epidemiology</i> , <b>1991</b> , 8, 209-16	2.6	2
55	Frequency of Contralateral Prophylactic Mastectomy in Breast Cancer Patients with a Negative BRCA1 and BRCA2 Rapid Genetic Test Result. <i>Annals of Surgical Oncology</i> , <b>2021</b> , 28, 4967-4973	3.1	2
54	DCIS and invasive interval breast cancer. <i>Lancet Oncology, The</i> , <b>2016</b> , 17, e87-e88	21.7	2
53	The relationship between the predicted risk of death and psychosocial functioning among women with early-stage breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2021</b> , 186, 177-189	4.4	2
52	The impacts of neoadjuvant chemotherapy and of cytoreductive surgery on 10-year survival from advanced ovarian cancer. <i>International Journal of Gynecology and Obstetrics</i> , <b>2021</b> , 153, 417-423	4	2
51	Survival from breast cancer in women with a BRCA2 mutation by treatment. <i>British Journal of Cancer</i> , <b>2021</b> , 124, 1524-1532	8.7	2
50	Germline pathogenic variants in BRCA1, BRCA2, PALB2 and RAD51C in breast cancer women from Argentina. <i>Breast Cancer Research and Treatment</i> , <b>2019</b> , 178, 629-636	4.4	1
49	Gender bias in CIHR Foundation grant awarding. <i>Lancet, The</i> , <b>2019</b> , 393, 2195	4.0	1
48	Long-term outcomes following a diagnosis of ovarian cancer at the time of preventive oophorectomy among and mutation carriers. <i>International Journal of Gynecological Cancer</i> , <b>2020</b> , 30, 825-830	3.5	1
47	Reply to Kopans. <i>Breast Cancer Research and Treatment</i> , <b>2017</b> , 166, 653-654	4.4	1
46	Reply to Hollingsworth: does breast cancer metastasize in the clinical window between the mammogram and the mass?. <i>Breast Cancer Research and Treatment</i> , <b>2018</b> , 169, 639-640	4.4	1
45	Genetic testing for young women with breast cancer. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, e182	21.7	1
44	Countercurrents: Is now the right time to pull the plug on mammography?. <i>Current Oncology</i> , <b>2019</b> , 26, 162-163	2.8	1

43	Inherited Variants in and the Risk and Clinical Characteristics of Breast Cancer. <i>Cancers</i> , <b>2019</b> , 11,	6.6	1
42	The authors reply. <i>American Journal of Epidemiology</i> , <b>2014</b> , 180, 760-1	3.8	1
41	Prostate cancer in a man with a BRCA2 mutation and a personal history of bilateral breast cancer. <i>Clinical Genetics</i> , <b>2015</b> , 88, 187-9	4	1
40	Personalized medicine: a personal view. <i>Current Oncology</i> , <b>2010</b> , 17, 4-5	2.8	1
39	Are bilateral cancers hereditary? Part II. <i>Current Oncology</i> , <b>2012</b> , 19, 246-7	2.8	1
38	Pathology and genetic testing. <i>Cancer</i> , <b>1997</b> , 80, 636-648	6.4	1
37	Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation.. <i>Gynecologic Oncology</i> , <b>2022</b> ,	4.9	1
36	Late Recurrences After Estrogen Receptor-Positive Breast Cancer. <i>JAMA Oncology</i> , <b>2020</b> , 6, 301-302	13.4	1
35	Preferences for breast cancer prevention among women with a or mutation. <i>Hereditary Cancer in Clinical Practice</i> , <b>2020</b> , 18, 20	2.3	1
34	Assessment of Secondary Sarcomas Among Patients With Cancer of the Abdomen or Pelvis Who Received Combinations of Surgery, Radiation, and Chemotherapy vs Surgery Alone. <i>JAMA Network Open</i> , <b>2020</b> , 3, e2013929	10.4	1
33	Breast cancer survival in Nordic BRCA2 mutation carriers-unconventional association with oestrogen receptor status. <i>British Journal of Cancer</i> , <b>2020</b> , 123, 1608-1615	8.7	1
32	The Screen Project: Guided Direct-To-Consumer Genetic Testing for Breast Cancer Susceptibility in Canada. <i>Cancers</i> , <b>2021</b> , 13,	6.6	1
31	PALB2 mutations and prostate cancer risk and survival. <i>British Journal of Cancer</i> , <b>2021</b> , 125, 569-575	8.7	1
30	Breast cancer risk after age 60 among BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , <b>2021</b> , 187, 515-523	4.4	1
29	Reply to P Mutations in RECQL are not associated with breast cancer risk in an Australian population? <i>Nature Genetics</i> , <b>2018</b> , 50, 1348-1349	36.3	1
28	Weight Gain and the Risk of Ovarian Cancer in and Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2021</b> , 30, 2038-2043	4	1
27	Analysis of BRCA1 mutations in a Pakistani family with hereditary breast and ovarian cancer syndrome <b>1998</b> , 78, 386		1
26	Risk of Second Primary Thyroid Cancer in Women with Breast Cancer.. <i>Cancers</i> , <b>2022</b> , 14,	6.6	1

25	Germline BRCA1 and BRCA2 mutations and the risk of bladder or kidney cancer in Poland.. <i>Hereditary Cancer in Clinical Practice</i> , <b>2022</b> , 20, 13	2.3	1
24	Association Between Invasive Lobular Breast Cancer and Mutations in the Mismatch Repair Gene MSH6. <i>JAMA Oncology</i> , <b>2019</b> , 5, 120	13.4	o
23	Author response to "a response to Personalised medicine and population health: breast and ovarian cancer". <i>Human Genetics</i> , <b>2019</b> , 138, 291-292	6.3	o
22	Re: Survival outcomes after contralateral prophylactic mastectomy: a decision analysis. <i>Journal of the National Cancer Institute</i> , <b>2015</b> , 107,	9.7	o
21	RE: Germline Mutations in the Kallikrein 6 Region and Predisposition for Aggressive Prostate Cancer. <i>Journal of the National Cancer Institute</i> , <b>2017</b> , 109,	9.7	o
20	In Response to "Pregnancy After Breast Cancer in Patients With Germline Mutations". <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 4352	2.2	o
19	Adjuvant olaparib - should all patients with breast cancer have genetic testing?. <i>Nature Reviews Clinical Oncology</i> , <b>2021</b> , 18, 607-608	19.4	o
18	The incidence of fatal breast cancer measures the increased effectiveness of therapy in women participating in mammography screening. <i>Cancer</i> , <b>2019</b> , 125, 2130	6.4	o
17	Genetic predisposition to male breast cancer in Poland. <i>BMC Cancer</i> , <b>2021</b> , 21, 975	4.8	o
16	Risk factors for psychological morbidity and the protective role of coping self-efficacy in young women with breast cancer early in diagnosis: a national multicentre cohort study.. <i>Breast Cancer Research and Treatment</i> , <b>2022</b> , 1	4.4	o
15	Prevalence of PALB2 mutations in the Creighton University Breast Cancer Family Registry. <i>Breast Cancer Research and Treatment</i> , <b>2015</b> , 150, 637-41	4.4	
14	Mammography screening for breast cancer-the UK Age trial. <i>Lancet Oncology, The</i> , <b>2020</b> , 21, e508	21.7	
13	Common genetic susceptibility to DCIS and invasive ductal carcinoma. <i>Breast Cancer Research</i> , <b>2016</b> , 18, 60	8.3	
12	Response to Evans et al. <i>Clinical Genetics</i> , <b>2016</b> , 89, 400	4	
11	Modern approaches to cancer prevention: Universal or personal?. <i>Journal of Cancer Policy</i> , <b>2014</b> , 2, 93-96	1	
10	Mutation Frequencies in Patients With Early-Onset Colorectal Cancer. <i>JAMA Oncology</i> , <b>2017</b> , 3, 1586-1587	13.4	
9	The therapeutic ratio is preserved for radiotherapy or cisplatin treatment in BRCA2-mutated prostate cancers. <i>Canadian Urological Association Journal</i> , <b>2013</b> , 5, 31	1.2	
8	Choices for young women at intermediate risk of breast cancer. <i>Current Oncology</i> , <b>2012</b> , 19, e112-4	2.8	

7	Regarding the use of tamoxifen post-oophorectomy to prevent hereditary breast cancer. <i>Hereditary Cancer in Clinical Practice</i> , <b>2006</b> , 4, 167-8	2.3
6	An evaluation of memory and attention in BRCA mutation carriers using an online cognitive assessment tool. <i>Cancer</i> , <b>2021</b> , 127, 3183-3193	6.4
5	Response to Comments on The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study. <i>British Journal of Cancer</i> , <b>2016</b> , 115, e4	8.7
4	Comparing Adjuvant vs Early-Salvage Radiotherapy After Radical Prostatectomy. <i>JAMA Oncology</i> , <b>2018</b> , 4, 1620	13.4
3	Cancer Risk Estimates for Study of Multiple-Gene Testing After Diagnosis of Breast Cancer. <i>JAMA Oncology</i> , <b>2018</b> , 4, 1787-1788	13.4
2	Influence of Germline BRCA Genotype on the Survival of Patients with Triple-Negative Breast Cancer. <i>Cancer Research Communications</i> , <b>2021</b> , 1, 140-147	
1	Common Variant in ALDH2 Modifies the Risk of Breast Cancer Among Carriers of the p.K3326* Variant in BRCA2.. <i>JCO Precision Oncology</i> , <b>2022</b> , 6, e2100450	3.6